Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

被引：0
|
作者：
Josep M. Llovet
Arndt Vogel
David C. Madoff
Richard S. Finn
Sadahisa Ogasawara
Zhenggang Ren
Kalgi Mody
Jerry J. Li
Abby B. Siegel
Leonid Dubrovsky
Masatoshi Kudo
机构：
[1] Tisch Cancer Institute,Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai
[2] University of Barcelona,Translational Research in Hepatic Oncology, IDIBAPS, Hospital Clinic Barcelona
[3] Institució Catalana d’Estudis Avançats (ICREA),Graduate School of Medicine
[4] Hannover Medical School,School of Medicine
[5] Yale School of Medicine and Yale Cancer Center/Smilow Cancer Hospital,undefined
[6] David Geffen School of Medicine at UCLA,undefined
[7] Chiba University,undefined
[8] Zhongshan Hospital Fudan University,undefined
[9] Eisai Inc,undefined
[10] Merck & Co.,undefined
[11] Inc,undefined
[12] Kindai University,undefined
来源：
CardioVascular and Interventional Radiology | 2022年 / 45卷
关键词：
Intermediate-stage hepatocellular carcinoma; Lenvatinib; Pembrolizumab; Transarterial chemoembolization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：405 / 412
页数：7
相关论文
共 50 条
  • [31] Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
    Chen, Lei
    Kan, Xuefeng
    Sun, Tao
    Ren, Yanqiao
    Cao, Yanyan
    Yan, Liangliang
    Liang, Bin
    Xiong, Bin
    Zheng, Chuansheng
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [32] Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen Lam
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 535 - 535
  • [33] Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review
    Ai, Haidong
    Gong, Ting
    Ma, Yongbiao
    Ma, Guixu
    Ding, Wei
    Ding, Weibao
    Wang, Wenjuan
    Zhao, Xuelin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [34] ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma
    Foerster, Friedrich
    Kloeckner, Roman
    Reig, Maria
    Chan, Stephen Lam
    Chung, Jin Wook
    Merle, Philippe
    Park, Joong-Won
    Piscaglia, Fabio
    Vogel, Arndt
    Gaillard, Vincent
    Bruix, Jordi
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [35] Effect of transarterial chemoembolization as postoperative adjuvant therapy for intermediate-stage hepatocellular carcinoma with microvascular invasion: a multicenter cohort study
    Xiang, Cailing
    Shen, Xianbo
    Zeng, Xinxin
    Zhang, Yuzhong
    Ma, Zhongzhi
    Zhang, Guocan
    Song, Xin
    Huang, Tao
    Yang, Juan
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (01) : 315 - 323
  • [36] A multicenter cohort study on transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma: Reconsidering combination-therapy trial design.
    Zhao, Yan
    Li, Hailiang
    Bai, Wei
    Liu, Jueshi
    Lv, Weifu
    Guan, Sheng
    Qin, Xiao
    Wang, Wenhui
    Ren, Weixin
    Mu, Wei
    Guo, Weidong
    Gu, Shanzhi
    Ma, Yilong
    Yin, Zhanxin
    Guo, Wengang
    Wang, Yongji
    Xia, Jielai
    Duran, Rafael
    Fan, Daiming
    Han, Guohong
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Harding, James J.
    Johnson, Matthew
    Palmer, Daniel H.
    Edeline, Julien
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Decaens, Thomas
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Galle, Peter R.
    Park, Joong-Won
    Yau, Thomas
    Begic, Damir
    Shen, Yun
    Neely, Jaclyn
    Sama, Ashwin Reddy
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma
    Llovet, Josep
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina
    Chen, Erluo
    Dubrovsky, Leonid
    Siegel, Abby
    Zhu, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [39] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Caihua Zhu
    Bing Dai
    Hua Zhan
    Ruoyu Deng
    Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1065 - 1071
  • [40] A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol (Mar, 10.1007/s00270-021-03010-0, 2022)
    Fidelman, Nicholas
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 45 (05) : 719 - 719
12345